Search results
How Is Ulcerative Colitis Treated?
Health.com· 1 week agoUlcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that affects the large intestine. Inflammation in the inner lining of the colon and...
FDA Approves Takeda’s Subcutaneous Form of Entyvio as a Maintenance Therapy in Adults with...
Pharmaceutical Executive Magazine· 1 week agoThe FDA has approved Takeda Pharmaceuticals’ subcutaneous (SC) form of Entyvio (vedolizumab) as a...
FDA approves Takeda's ENTYVIO for Crohn's disease
Investing.com· 1 week agoFDA approves Takeda's ENTYVIO for Crohn's disease
FDA approves Takeda’s self-administered Entyvio for Crohn’s disease
BioPharma-Reporter· 4 days agoThe news comes after SC Entyvio was previously approved by the FDA in September 2023 for adults with...
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
Morningstar· 1 week agoTakeda Pharmaceutical said the U.S. Food and Drug Administration has approved subcutaneous administration of Entyvio as a maintenance therapy for adults with Crohn's disease ...
Dr. Roach: Eye drops safe to use with AMD medication
Detroit News· 1 day agoDear Dr. Roach: I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). Is it safe to use over-the-counter eye drops? Dear C.H.: Eylea is used ...
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 4 days agoSource: Author's elaboration, based on GuruFocus data. According to our assessment, the key contributor to improving Takeda's financial position is ...
Pfizer’s Velsipity UK approval to raise competition in ulcerative colitis market
BioPharma-Reporter· 2 weeks agoWith the approval, the drug will increase the competition in the UC market, where multiple players...
FDA OKs Sub-Q Vedolizumab for Crohn's Maintenance Therapy
Medscape· 1 week agoSubcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn's disease after induction therapy with intravenous vedolizumab.
